Understanding EGAPP

Related Pages

Steps in the EGAPP Working Group Review Process

1 Select Test Topic Products: Priortized topic lists

2 Commission & Conduct Evidence Review Products: Evidence Reports & published/posted summaries

3 Develop Evidence-Based Recommendation Statement Products: Peer-reviewed, published Recommendation Statements

4 Disseminate EGAPP Products & Communicate Informational Messages to Stakeholders

Review Process
 Group Topics Evidence Report Recommendation Statement Dissemination
EGAPP Working Group (EWG) aqua dot blue dot
EGAPP consultants and CDC-based staff aqua dot red dot blue dot green dot
EWG members who serve on Technical Expert Panel   red dot blue dot
green dot
 EWG who serve on the recommendation writing team blue dot green dot
Stakeholders and interested public aqua dot green dot
Evidence-based Practice Centers (EPc) and other review groups red dot green dot
Expert and /or peer reviewers red dot blue dot
Industry/test developer*
invited comment on the final evidence report		 aqua dot red dot
Step 1: Select Test Topic

Summary: Process for identifying, prioritizing, and selecting tests and specific clinical scenarios for systematic review.

Who is involved: EGAPP Working Group (EWG) Topics Subcommittee, full EWG, CDC-based EGAPP staff, and interested public. See process diagram below for details.

Transparency: EGAPP welcomes suggestions on potential topics for review. Those submitting suggestions are
encouraged to include information on the disorder, the specific test(s), and the specific clinical
scenario(s) in which the test will be used. EGAPP Working Group members make final topic selections.

Products:

  • List of topics
  • Key questions and analytic framework for evidence reviews
Topic Selection Process
chart 2

Step 2: Commission & Conduct Evidence Review

Summary: An evidence review involves many steps and is meant to synthesize available evidence on a particular disorder, test, and clinical scenario.

CDC commissions systematic evidence reviews using two strategies:

  • Comprehensive Reviews are usually done in partnership with Agency for Healthcare Research and Quality Evidence-based Practice Centers (AHRQ EPCs). EPCs conduct comprehensive literature searches and evaluation, with detailed
    documentation of methods and results.
  • Targeted and/or Rapid Reviews are conducted for topics with minimal literature to review and/or targeted questions to answer. These reviews are coordinated by CDC-based EGAPP staff in collaboration with technical contractors and expert core consultants.

Evidence reports, the products of these reviews, are detailed, systematic, objective assessments of the available scientific and
clinical evidence on a specific topic. Evidence reports are the basis for deliberations by the EGAPP Working Group as they develop
their Recommendation Statements.

Who is involved: CDC commissions the review, the EWG develops the key questions to be addressed, and the selected review team (e.g., EPC or other contracted group) conducts the review and produces a report. The review team establishes a Technical Expert Panel (TEP) to provide guidance, usually including topic experts and two to three EWG members.

Transparency: All EGAPP Working Group members, review team members, and consultants disclose potential conflicts of interest
for each topic considered. Evidence reports undergo external expert review. Reports or manuscripts published with CDC staff as authors may undergo CDC clearance.

Products:

Evidence reports posted on web sites (EGAPP or AHRQ)

Published summaries of evidence from the AHRQ EPCs or other contracted review group.

EGAPP EVIDENCE REVIEW PROCESS
diagram
Comprehensive EPC Reviews

Conducted by Agency for Healthcare Research and Quality Evidence-based Practice Centers


Technical Expert Panel (TEP) by EPC established to guide review

  • The TEP includes topic experts and 2-3 EWG members to finalize key questions and guide the scope and content of the review.


Evidence report drafted

  • Evidence reviewers solicit comments on draft evidence report from TEP, EWG, and expert reviewers selected by the EPC.


Final evidence report provided to AHRQ

Optional: EPC publishes summary manuscript in journal

Rapid and/or Targeted Reviews

Conducted by reviewers who may include:

  • Core EGAPP consultants in with expertise in evidence-based review
  • Consultants in specific topic areas (e.g., oncology)
  • CDC-based technical EGAPP staff


TEP established to guide review

  • The TEP includes topic experts and 2-3 EWG members to finalize key questions and guide the scope and content of the review.


Evidence report drafted

  • Evidence reviewers solicit comments on draft evidence report from TEP, EWG, and expert reviewers selected by the review group.


Final evidence report provided to CDC and EWG

  • Approved by EWG
  • If CDC authors, cleared by CDC
  • EWG provides final report to selected test developers for comment to aid in developing Recommendation Statement
  • Final evidence report posted on EWG web site
  • Evidence summary is prepared for submission to journal

In some cases, the EWG may request additional information, analysis, or targeted review to address questions that arise as part of the development of the Recommendation Statement.

Step 3: Develop Evidence-based Recommendation Statements

Summary: The EGAPP Working Group (EWG) reviews the evidence report, considers contextual issues, and may consider other
sources of evidence. A draft recommendation statement is developed, peer-reviewed, and submitted for publication.

EWG Recommendation Statements are based on CDC-commissioned evidence reports, other review of evidence as needed, the quality of available data, and potential clinical and social impact of using the test in practice.

Who is involved: EWG, with support from CDC-based EGAPP staff and consultants.

Transparency: Review of comments from industry and a range of stakeholders (e.g., from professional organizations, health plans, consumer groups, and public health programs).

Products:

Peer-reviewed, published EWG Recommendation Statements

Recommendation Statement Development Process
chart

Step 4: Dissiminate EGAPP prodects and Communicate Informational Messages to Stakeholders

Summary: EGAPP initiative products are disseminated to stakeholders through publications, web sites, and presentations.

 

Who is involved: CDC-based EGAPP staff, EGAPP Stakeholders Group (ESG), EGAPP Working Group (EWG).

 

Transparency: Stakeholder peer review, CDC clearance.

Dissemination Processes for EGAPP Products and Informational Messages

 

arrows

Primary EGAPP products

Commissioned evidence reports

  • Posted on EWG website or Agency for Healthcare Research and Quality website

EWG Recommendation Statements

  • Published in peer-reviewed journal
    • Free web access to article
    • Journal may issue press release

EWG website

  • Open access

Secondary EGAPP products

Announcements of EGAPP initiative primary products and other updates (CDC-based EGAPP staff)

  • Posted on the website of the CDC Office of Public Health Genomics (OPHG), which supports the EGAPP initiative.
  • Posted on the EWG website
  • Distributed by e-mail across CDC and to EGAPP stakeholder list (approximately 400 genetic testing stakeholder organizations and individuals)

EGAPP informational messages incorporated into translational materials for providers and consumers (CDC-based EGAPP staff, ESG)

  • Posted on CDC OPHG web pages
  • Disseminated by various means through diverse EGAPP Stakeholders Group organizations

CDC Press Statements related to EGAPP (CDC-based EGAPP staff and CDC press office)

  • Posted on CDC web pages for Media

EGAPP initiative web pages on CDC website (CDC-based EGAPP staff)

  • Posted on CDC OPHG web pages

EGAPP initiative posters and presentations (CDC EGAPP staff, EWG, ESG)

For more information see EGAPP FAQs or CDC EGAPP Initiative.

Primary EGAPP products
Commissioned evidence reports
  • Posted on EWG website or Agency for Healthcare Research and Quality website
EWG Recommendation Statements
  • Published in peer-reviewed journal
    • Free web access to article
    • Journal may issue press release
EWG website
  • Open access

Secondary EGAPP products
Announcements of EGAPP initiative primary products and other updates (CDC-based EGAPP staff)
  • Posted on the website of the CDC Office of Public Health Genomics (OPHG), which supports the EGAPP initiative.
  • Posted on the EWG website
  • Distributed by e-mail across CDC and to EGAPP stakeholder list (approximately 400 genetic testing stakeholder organizations and individuals)
EGAPP informational messages incorporated into translational materials for providers and consumers (CDC-based EGAPP staff, ESG)
  • Posted on CDC OPHG web pages
  • Disseminated by various means through diverse EGAPP Stakeholders Group organizations
CDC Press Statements related to EGAPP (CDC-based EGAPP staff and CDC press office)
  • Posted on CDC web pages for Media
EGAPP initiative web pages on CDC website (CDC-based EGAPP staff)
  • Posted on CDC OPHG web pages
EGAPP initiative posters and presentations (CDC EGAPP staff, EWG, ESG)

View Page In:Cdc-pdf PDF [1M]
Page last reviewed: December 6, 2016 (archived document)
Content source: Evaluation of Genomic Applications in Practice and Prevention (EGAPP)